AGTR1

Summary

AGTR1 (angiotensin II receptor type 1, HGNC:336) is a protein-coding gene on chromosome 3q24, encoding Type-1 angiotensin II receptor (P30556). Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator of blood pressure and sodium retention by the kidney.

Angiotensin II is a potent vasopressor hormone and a primary regulator of aldosterone secretion. It is an important effector controlling blood pressure and volume in the cardiovascular system. It acts through at least two types of receptors. This gene encodes the type 1 receptor which is thought to mediate the major cardiovascular effects of angiotensin II. This gene may play a role in the generation of reperfusion arrhythmias following restoration of blood flow to ischemic or infarcted myocardium. It was previously thought that a related gene, denoted as AGTR1B, existed; however, it is now believed that there is only one type 1 receptor gene in humans. Alternative splicing of this gene results in multiple transcript variants.

Source: NCBI Gene 185 — RefSeq curated summary.

At a glance

• Gene–disease (curated): renal tubular dysgenesis of genetic origin (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 6
• Clinical variants (ClinVar): 184 total — 5 pathogenic, 9 likely-pathogenic
• Phenotypes (HPO): 15
• Druggable target: yes — 88 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_000685

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:336
Approved symbol	AGTR1
Name	angiotensin II receptor type 1
Location	3q24
Locus type	gene with protein product
Status	Approved
Aliases	AT1, AT2R1, AGTR1A, AT2R1A, HAT1R, AG2S, AT2R1B, AT1B, ATR1
Ensembl gene	ENSG00000144891
Ensembl biotype	protein_coding
OMIM	106165
Entrez	185

Gene structure

Transcript identifiers

Ensembl transcripts: 28 — 27 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000349243, ENST00000402260, ENST00000404754, ENST00000418473, ENST00000461609, ENST00000474935, ENST00000475166, ENST00000475347, ENST00000497524, ENST00000892854, ENST00000892855, ENST00000892856, ENST00000892857, ENST00000892858, ENST00000892859, ENST00000892860, ENST00000892861, ENST00000892862, ENST00000892863, ENST00000892864, ENST00000892865, ENST00000892866, ENST00000892867, ENST00000892868, ENST00000892869, ENST00000944541, ENST00000944542, ENST00000944543

RefSeq mRNA: 7 — MANE Select: NM_000685 NM_000685, NM_001382736, NM_001382737, NM_004835, NM_009585, NM_031850, NM_032049

CCDS: CCDS3137

Canonical transcript exons

ENST00000349243 — 3 exons

Exon	Start	End
ENSE00001249603	148707944	148708027
ENSE00001249611	148697903	148698127
ENSE00001837679	148740989	148743003

Expression profiles

Bgee: expression breadth ubiquitous, 224 present calls, max score 96.35.

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skin of hip	UBERON:0001554	96.35	gold quality
placenta	UBERON:0001987	95.02	gold quality
subcutaneous adipose tissue	UBERON:0002190	94.83	gold quality
liver	UBERON:0002107	94.31	gold quality
right lobe of liver	UBERON:0001114	94.29	gold quality
adipose tissue	UBERON:0001013	93.48	gold quality
right adrenal gland	UBERON:0001233	92.77	gold quality
left adrenal gland	UBERON:0001234	92.64	gold quality
adrenal cortex	UBERON:0001235	92.31	gold quality
left adrenal gland cortex	UBERON:0035825	92.25	gold quality
right adrenal gland cortex	UBERON:0035827	92.21	gold quality
connective tissue	UBERON:0002384	92.06	gold quality
adipose tissue of abdominal region	UBERON:0007808	91.89	gold quality
adrenal gland	UBERON:0002369	91.72	gold quality
omental fat pad	UBERON:0010414	91.71	gold quality
peritoneum	UBERON:0002358	91.63	gold quality
parietal pleura	UBERON:0002400	91.02	gold quality
lower lobe of lung	UBERON:0008949	89.40	gold quality
mucosa of stomach	UBERON:0001199	88.82	gold quality
diaphragm	UBERON:0001103	88.16	silver quality
thoracic mammary gland	UBERON:0005200	87.87	gold quality
mammary gland	UBERON:0001911	87.60	gold quality
synovial joint	UBERON:0002217	87.51	gold quality
right lung	UBERON:0002167	87.46	gold quality
adrenal tissue	UBERON:0018303	87.37	gold quality
muscle layer of sigmoid colon	UBERON:0035805	87.08	gold quality
pleura	UBERON:0000977	87.07	gold quality
pericardium	UBERON:0002407	86.09	gold quality
upper leg skin	UBERON:0004262	85.61	gold quality
tibialis anterior	UBERON:0001385	85.49	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-24	yes	1250.28
E-MTAB-6701	yes	1027.49
E-ANND-3	yes	34.02

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
PAX2	Activation

Upstream regulators (CollecTRI, top): AP1, AR, CREB1, CREM, CUX1, ELK1, ETV4, GATA4, HIF1A, KLF4, MEF2A, MYC, NFKB, NR1H3, PPARA, PPARG, SMAD2, SMAD3, SMAD4, SND1, SP1, SP3, VDR

miRNA regulators (miRDB)

84 targeting AGTR1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488

Literature-anchored findings (GeneRIF, showing 40)

• Generated a new transgenic rat model that exhibits an upregulated myocardial AT1 receptor density and demonstrates augmented cardiac hypertrophy and contractile response to angiotensin II after volume and pressure overload. (PMID:11692158)
• Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. (PMID:11799082)
• Lys(199) mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists. (PMID:11881039)
• role in familial hyperaldosteronism (PMID:11903322)
• Polymorphisms of genes encoding the AT1 receptor as risk factors for orthostatic hypotension. (PMID:11910300)
• angiotensinogen T174M and M235T and the AT1-receptor A1166C polymorphisms were related to the change in LVH during antihypertensive treatment with an AT1-receptor antagonist (PMID:11910301)
• Adenine/cytosine1166 polymorphism is not associated with mitral valve prolapse syndrome in Taiwan Chinese. (PMID:11999641)
• angiotensin IV is a potent agonist for constitutive active human AT1 receptor (PMID:12006574)
• Stimulation of the Ang II type 1 receptor by Ang II reduced adipose conversion, whereas blockade of this receptor markedly enhanced adipogenesis. (PMID:12031955)
• Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin (PMID:12045255)
• AT1R gene contributes to the development of essential hypertension. (PMID:12048678)
• AT1 receptor antagonism improves endothelial function during hypercholesterolemia. (PMID:12117739)
• Type I Ang II receptor subtype (AT1) mediates Ang II-dependent [Ca2+]i increase in cancerous breast cells in culture (PMID:12127057)
• explore the relation among myocardial AT(1)-/AT(2)- receptor expression, myocardial remodeling and cardiac function in patients with congestive heart failure (PMID:12133421)
• that the presence of C allele of the AT1R locus polymorphism might be associated with faster deterioration of renal function in renal failure (PMID:12187084)
• A1166C polymorphism of the angiotensin II type 1 receptor gene and essential hypertension in Han, Tibetan and Yi populations. (PMID:12358135)
• AT1R gene contributed to T2DM complicated by hypertension, but is only associated with cases of elevated systolic blood pressure. (PMID:12390711)
• results suggest that the caveolin-binding-like motif of the angiotensin II type 1 receptor may act as a docking site for regulatory proteins modulating the routing and the functionality of the receptor (PMID:12446598)
• The angiotensin II (Ang II) molecule must adopt an extended structure when ligand incorporation occurs on the C-terminal Ang II fragment at residues Phe-293 and Asn-294 of the seventh transmembrane domain of the AT1 receptor. (PMID:12450401)
• in this large cohort of older adults, the A1166C polymorphism was not associated with BP control or incident cardiovascular events (PMID:12460700)
• The results for the AT1R gene polymorphism revealed significant differences in allele and genotype frequencies. (PMID:12476891)
• Analysis of A1166C polymorphism in Serbian hypertensives showed significant association between hypertension and CC genotype in the males only. (PMID:12482634)
• Tyr-319 of the AT1 receptor is phosphorylated in response to Ang II and plays a key role in mediating Ang II-induced transactivation of EGFR and cell proliferation, possibly through its interaction with SHP-2 and EGFR (PMID:12522132)
• angiotensin II AT(1) receptor autoantibodies (anti-AT(1)-AABs) in preeclamptic women (PMID:12534336)
• Association of ACE I/D and AT(1)R-A C polymorphisms with BP in a healthy normotensive primary care population. Although synergistic effect of both polymorphisms on BP does not seem to be present, an additive effect on DBP is likely. (PMID:12544439)
• Importance of alternative splicing as an additional post-transcriptional mechanism regulating human AT(1) receptor number and function. (review) (PMID:12591176)
• Our findings suggest that maternal autoantibody with the ability to activate AT1 receptors may account for two features of preeclampsia, increased PAI-1 production and shallow trophoblast invasion (PMID:12593997)
• Polymorphism in essential arterial hypertension in childhood. (PMID:12597535)
• the A1166C polymorphism of AT1 receptor is unlikely to influence blood pressure status in the Japanese population. (PMID:12627871)
• that AT1 A/C1166 polymorphism was not associated with any clinical parameters associated with hypertension or atherosclerosis in the Japanese population. (PMID:12627873)
• In young healthy subjects, there is an important interaction between gender, the AGT1R A1166–>C gene polymorphism, and blood pressure. (PMID:12631360)
• mRNA levels as well as the protein production of angiotensin II receptors of type 1 was monitored during differentiation of primary human preadipocytes in culture and in mature adipocytes. (PMID:12660887)
• Polymorphism is associated with diabetic retinopathy in NIDDM in Chinese patients. (PMID:12716844)
• Susceptibility to faster progression to ESRD is associated with the AT1R A1166C polymorphism. (PMID:12832734)
• activation of the angiotensin II type 1 receptor alters the spatial proximity of transmembrane 7 to the ligand-binding pocket (PMID:12842881)
• Placental AT1R expression and its normal vascular and endocrine activity plays a very important role in oxygenation and nutrition of the fetus and this ensures proper fetal development and growth. (PMID:12860335)
• results confirmed that angiotensin II receptor type 1 immunoreactivity is elevated in vascular endothelial cells of human placenta from pregnancies complicated by preeclampsia (PMID:12897464)
• Polymorphisms of the angiotensin II receptor, type 1 gene is associated with increased risk of coronary heart disease in hypertension. (PMID:12925562)
• findings suggest that the angiotensinogen and angiotensin II type 1 receptor gene polymorphisms would not have an effect on hypertension or the end stage renal disease in autosomal dominant polycystic kidney disease (PMID:12950120)
• the N111G-AT1 receptor maintains a high affinity conformation despite being uncoupled from the G protein Gq/11. (PMID:12960024)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	agtr1a	ENSDARG00000018616
danio_rerio	agtr1b	ENSDARG00000045443
mus_musculus	Agtr1a	ENSMUSG00000049115
mus_musculus	Agtr1b	ENSMUSG00000054988
rattus_norvegicus	Agtr1b	ENSRNOG00000010640
rattus_norvegicus	Agtr1a	ENSRNOG00000018346

Paralogs (7): BDKRB1 (ENSG00000100739), APLNR (ENSG00000134817), GPR15 (ENSG00000154165), BDKRB2 (ENSG00000168398), GPR25 (ENSG00000170128), RXFP4 (ENSG00000173080), AGTR2 (ENSG00000180772)

Protein

Protein identifiers

Type-1 angiotensin II receptor — P30556 (reviewed: P30556)

Alternative names: AT1AR, AT1BR, Angiotensin II type-1 receptor

All UniProt accessions (4): P30556, A0A0A0MSE3, D3DNG8, Q53YY0

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator of blood pressure and sodium retention by the kidney. The activated receptor in turn couples to G-alpha proteins G(q) (GNAQ, GNA11, GNA14 or GNA15) and thus activates phospholipase C and increases the cytosolic Ca(2+) concentrations, which in turn triggers cellular responses such as stimulation of protein kinase C. (Microbial infection) During SARS coronavirus-2/SARS-CoV-2 infection, it is able to recognize and internalize the complex formed by secreted ACE2 and SARS-CoV-2 spike protein through DNM2/dynamin 2-dependent endocytosis.

Subunit / interactions. Interacts with MAS1. Interacts with ARRB1. Interacts with FLNA (via filamin repeat 21); increases PKA-mediated phosphorylation of FLNA.

Subcellular location. Cell membrane.

Tissue specificity. Liver, lung, adrenal and adrenocortical adenomas.

Post-translational modifications. C-terminal Ser or Thr residues may be phosphorylated.

Disease relevance. Renal tubular dysgenesis (RTD) [MIM:267430] Autosomal recessive severe disorder of renal tubular development characterized by persistent fetal anuria and perinatal death, probably due to pulmonary hypoplasia from early-onset oligohydramnios (the Potter phenotype). The disease is caused by variants affecting the gene represented in this entry.

Activity regulation. Strongly inhibited by anti-hypertensive drugs losartan, candesartan, valsartan, irbesartan, telmisartan, eprosartan, olmesartan and azilsartan, most of which share a common biphenyl-tetrazole scaffold.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (7): NP_000676, NP_001369665, NP_001369666, NP_004826, NP_033611, NP_114038, NP_114438 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000190	ATII_AT1_rcpt	Family
IPR000248	ATII_rcpt	Family
IPR000276	GPCR_Rhodpsn	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain
IPR050119	CCR1-9-like	Family

Pfam: PF00001

UniProt features (81 total): mutagenesis site 14, helix 13, topological domain 8, transmembrane region 7, binding site 7, sequence variant 7, sequence conflict 6, strand 5, turn 5, glycosylation site 3, disulfide bond 2, chain 1, region of interest 1, compositionally biased region 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

11 structures.

PDB	Method	Resolution (Å)
6OS2	X-RAY DIFFRACTION	2.7
6OS1	X-RAY DIFFRACTION	2.79
4ZUD	X-RAY DIFFRACTION	2.8
4YAY	X-RAY DIFFRACTION	2.9
6OS0	X-RAY DIFFRACTION	2.9
6DO1	X-RAY DIFFRACTION	2.9
8TH3	ELECTRON MICROSCOPY	3
9EAH	ELECTRON MICROSCOPY	3.1
9EAI	ELECTRON MICROSCOPY	3.1
9EAJ	ELECTRON MICROSCOPY	3.2
8TH4	ELECTRON MICROSCOPY	3.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P30556-F1	82.55	0.58

Antibody-complex structures (SAbDab): 5 — 6DO1, 6OS0, 6OS1, 6OS2, 8TH4

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (7): 15; 17; 167; 182; 183; 184; 199

Post-translational modifications (1): 355

Disulfide bonds (2): 18–274, 101–180

Glycosylation sites (3): 4, 176, 188

Mutagenesis-validated functional residues (14):

Position	Phenotype
35	abolished binding to angiotensin ii; abolished binding to olmesartan inhibitor.
84	abolished binding to angiotensin ii; abolished binding to olmesartan inhibitor.
92	decreased binding to telmisartan inhibitor.
111	reduced affinity for angiotensin ii.
111	induces a conformational change in the angiotensin ii-binding pocket, leading to constitutive activation of the receptor
112	increased affinity for angiotensin ii.
135	abolished binding to angiotensin ii.
167	abolished binding to angiotensin ii; abolished binding to olmesartan inhibitor.
182	reduced binding to angiotensin ii without affecting binding to candesartan inhibitor.
199	abolished binding to angiotensin ii.
284	slightly affects binding to eprosartan inhibitor.
285	decreased binding to eprosartan inhibitor.
288	decreased binding to eprosartan inhibitor.
292	mimics the disordered side chain induced by angiotensin ii-binding; increased affinity for g-protein subunit alpha prote

Function

Pathways and Gene Ontology

Reactome pathways

11 pathways

ID	Pathway
R-HSA-375276	Peptide ligand-binding receptors
R-HSA-416476	G alpha (q) signalling events
R-HSA-8856825	Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828	Clathrin-mediated endocytosis
R-HSA-162582	Signal Transduction
R-HSA-199991	Membrane Trafficking
R-HSA-372790	Signaling by GPCR
R-HSA-373076	Class A/1 (Rhodopsin-like receptors)
R-HSA-388396	GPCR downstream signalling
R-HSA-500792	GPCR ligand binding
R-HSA-5653656	Vesicle-mediated transport

MSigDB gene sets: 338 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_DN, GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, GOBP_EXCRETION, MODULE_416, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, chr3q24, GOBP_REGULATION_OF_BLOOD_PRESSURE, GOBP_CIRCULATORY_SYSTEM_PROCESS, GOBP_CELL_CHEMOTAXIS, GOBP_INFLAMMATORY_RESPONSE, MODULE_64, KAAB_HEART_ATRIUM_VS_VENTRICLE_UP, GOBP_RESPONSE_TO_ANGIOTENSIN, GOBP_GROWTH, GOBP_REGULATION_OF_SYSTEMIC_ARTERIAL_BLOOD_PRESSURE

GO Biological Process (27): regulation of cell growth (GO:0001558), kidney development (GO:0001822), renin-angiotensin regulation of aldosterone production (GO:0002018), maintenance of blood vessel diameter homeostasis by renin-angiotensin (GO:0002034), regulation of systemic arterial blood pressure by renin-angiotensin (GO:0003081), inflammatory response (GO:0006954), G protein-coupled receptor signaling pathway (GO:0007186), phospholipase C-activating G protein-coupled receptor signaling pathway (GO:0007200), positive regulation of cytosolic calcium ion concentration (GO:0007204), Rho protein signal transduction (GO:0007266), positive regulation of macrophage derived foam cell differentiation (GO:0010744), regulation of vasoconstriction (GO:0019229), calcium-mediated signaling (GO:0019722), low-density lipoprotein particle remodeling (GO:0034374), regulation of renal sodium excretion (GO:0035813), angiotensin-activated signaling pathway (GO:0038166), regulation of cell population proliferation (GO:0042127), symbiont entry into host cell (GO:0046718), regulation of inflammatory response (GO:0050727), positive regulation of inflammatory response (GO:0050729), cell chemotaxis (GO:0060326), phospholipase C-activating angiotensin-activated signaling pathway (GO:0086097), positive regulation of cholesterol metabolic process (GO:0090205), blood vessel diameter maintenance (GO:0097746), positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis (GO:1903589), positive regulation of reactive oxygen species metabolic process (GO:2000379), signal transduction (GO:0007165)

GO Molecular Function (6): angiotensin type I receptor activity (GO:0001596), angiotensin type II receptor activity (GO:0004945), bradykinin receptor binding (GO:0031711), protein heterodimerization activity (GO:0046982), G protein-coupled receptor activity (GO:0004930), protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-8 pathways:

Category	Pathways
Signaling by GPCR	2
Class A/1 (Rhodopsin-like receptors)	1
GPCR downstream signalling	1
Clathrin-mediated endocytosis	1
Membrane Trafficking	1
Vesicle-mediated transport	1
Signal Transduction	1
GPCR ligand binding	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
G protein-coupled receptor signaling pathway	3
blood vessel diameter maintenance	2
inflammatory response	2
angiotensin receptor activity	2
cell growth	1
regulation of growth	1
regulation of cellular component organization	1
animal organ development	1
renal system development	1
regulation of blood volume by renin-angiotensin	1
renal system process involved in regulation of systemic arterial blood pressure	1
aldosterone secretion	1
regulation of aldosterone secretion	1
regulation of systemic arterial blood pressure by renin-angiotensin	1
regulation of systemic arterial blood pressure by hormone	1
defense response	1
G protein-coupled receptor activity	1
signal transduction	1
phospholipase C activator activity	1
regulation of biological quality	1
small GTPase-mediated signal transduction	1
macrophage derived foam cell differentiation	1
regulation of macrophage derived foam cell differentiation	1
positive regulation of cell differentiation	1
vasoconstriction	1
regulation of blood circulation	1
intracellular signaling cassette	1
plasma lipoprotein particle remodeling	1
renal sodium excretion	1
regulation of excretion	1
regulation of renal system process	1
cellular response to angiotensin	1
cell population proliferation	1
regulation of cellular process	1
viral life cycle	1
symbiont entry into host	1
regulation of defense response	1
regulation of response to external stimulus	1
positive regulation of defense response	1
positive regulation of response to external stimulus	1

Protein interactions and networks

STRING

2434 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
AGTR1	AGT	P01019	999
AGTR1	ACE2	Q9BYF1	996
AGTR1	ACE	P12821	975
AGTR1	AGTRAP	Q6RW13	974
AGTR1	GNAQ	P50148	971
AGTR1	REN	P00797	969
AGTR1	BDKRB2	P30411	945
AGTR1	KNG1	P01042	938
AGTR1	ARRB2	P32121	872
AGTR1	CYP11B2	P19099	871
AGTR1	AGTR2	P50052	835
AGTR1	ADRB2	P07550	791
AGTR1	MAS1L	P35410	790
AGTR1	ARRB1	P49407	790
AGTR1	EDN1	P05305	785

IntAct

91 interactions, top by confidence:

A	B	Type	Score
AGTR1	APLNR	psi-mi:“MI:0915”(physical association)	0.710
AGTR1	APLNR	psi-mi:“MI:2364”(proximity)	0.710
APLNR	AGTR1	psi-mi:“MI:0915”(physical association)	0.710
AGTR1	ATP1B1	psi-mi:“MI:0915”(physical association)	0.510
AGTR1	CERS6	psi-mi:“MI:0915”(physical association)	0.510
AGTR1	DNAJC8	psi-mi:“MI:0915”(physical association)	0.510
AGTR1	OAZ1	psi-mi:“MI:0915”(physical association)	0.510
ATP1B1	AGTR1	psi-mi:“MI:0915”(physical association)	0.510
DNAJC8	AGTR1	psi-mi:“MI:0915”(physical association)	0.510
CERS6	AGTR1	psi-mi:“MI:0915”(physical association)	0.510
OAZ1	AGTR1	psi-mi:“MI:0915”(physical association)	0.510
AGTR1	VAC14	psi-mi:“MI:0915”(physical association)	0.400
AGTR1	AGT	psi-mi:“MI:0915”(physical association)	0.400
RAMP2	AGTR1	psi-mi:“MI:0915”(physical association)	0.400
AGTR1	RAMP3	psi-mi:“MI:0915”(physical association)	0.400
RAMP3	AGTR1	psi-mi:“MI:0915”(physical association)	0.400
AGTR1	RAMP2	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (126): PDE6H (Two-hybrid), VKORC1L1 (Affinity Capture-MS), ATP12A (Affinity Capture-MS), ATP2B4 (Affinity Capture-MS), ATP2B3 (Affinity Capture-MS), PIGU (Affinity Capture-MS), CLCC1 (Affinity Capture-MS), THOC7 (Affinity Capture-MS), SETD7 (Affinity Capture-MS), SLC6A8 (Affinity Capture-MS), ALG10 (Affinity Capture-MS), CAV1 (Affinity Capture-MS), SLC19A2 (Affinity Capture-MS), C1orf112 (Affinity Capture-MS), TMEM11 (Affinity Capture-MS)

ESM2 similar proteins: O00574, O18793, O18983, O19024, O35210, O55193, O77590, O97881, O97882, P25095, P25104, P29089, P29754, P29755, P30555, P30556, P32303, P33396, P34976, P35351, P35373, P35374, P43240, P50052, P51678, P51681, P51683, P56440, P56493, P60574, P61756, P79785, Q28929, Q2HJ17, Q5ECR9, Q64H34, Q6WN98, Q8HZT9, Q95NC2, Q95NC3

Diamond homologs: A0T2N3, F1MV99, O00155, O00590, O08707, O08858, O09027, O35210, O77590, O88410, O89039, O97666, P0C5I1, P0C7U4, P11613, P21109, P25024, P25025, P25095, P25104, P25106, P29089, P29754, P29755, P30555, P30556, P30680, P30874, P30875, P30935, P30936, P30937, P30938, P31391, P32303, P32745, P33396, P33535, P34976, P34993

SIGNOR signaling

25 interactions.

A	Effect	B	Mechanism
AGTR1	up-regulates	GNAQ	binding
AGT	up-regulates	AGTR1	binding
AGTR1	up-regulates	GNA13	binding
AGTR1	up-regulates	GNG12	binding
AGTR1	“up-regulates activity”	GNAI1	binding
AGTR1	“up-regulates activity”	GNAI3	binding
AGTR1	“up-regulates activity”	GNAQ	binding
AGTR1	“up-regulates activity”	GNA14	binding
AGTR1	“up-regulates activity”	GNA15	binding
“Ile(5)-angiotensin II”	“up-regulates activity”	AGTR1	“chemical activation”
eprosartan	“down-regulates activity”	AGTR1	“chemical inhibition”
valsartan	“down-regulates activity”	AGTR1	“chemical inhibition”
telmisartan	“down-regulates activity”	AGTR1	“chemical inhibition”
AGTR1	up-regulates	Inflammation
AGTR1	up-regulates	Fibrosis
Angiotensin-2	“up-regulates activity”	AGTR1	binding
MAS1	“down-regulates activity”	AGTR1	binding
hsa-miR-155-5p	“down-regulates quantity by repression”	AGTR1	“post transcriptional regulation”
hsa-miR-410-3p	“down-regulates quantity by repression”	AGTR1	“post transcriptional regulation”
AGTR1	“up-regulates activity”	GNA11	binding
AGTR1	up-regulates	Membrane_blebbing
hsa-miR-410-3p	“down-regulates quantity by destabilization”	AGTR1	“post transcriptional regulation”
AGTR1	“up-regulates quantity by expression”	PAX2	“transcriptional regulation”
AGT	“up-regulates activity”	AGTR1	binding
AGTR1	“down-regulates activity”	NPHS1

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 69 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
protein transport	9	6.2×	8e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

184 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	5
Likely pathogenic	9
Uncertain significance	113
Likely benign	29
Benign	18

Top pathogenic / likely-pathogenic (14)

Variant ID	HGVS	Classification
1685512	NM_000685.5(AGTR1):c.233del (p.Leu78fs)	Pathogenic
18067	NM_000685.5(AGTR1):c.845C>T (p.Thr282Met)	Pathogenic
3246874	NC_000003.11:g.(?148447967)(149678891_?)del	Pathogenic
4700197	NM_000685.5(AGTR1):c.-47-10764C>T	Pathogenic
50206	NM_000685.5(AGTR1):c.251G>A (p.Trp84Ter)	Pathogenic
1179033	NM_000685.5(AGTR1):c.599dup (p.Asn200fs)	Likely pathogenic
1184963	NM_000685.5(AGTR1):c.696_700del (p.Pro233fs)	Likely pathogenic
1328400	NM_000685.5(AGTR1):c.879del (p.Phe293fs)	Likely pathogenic
18066	NM_000685.5(AGTR1):c.110dup (p.Ile38fs)	Likely pathogenic
3588650	NM_000685.5(AGTR1):c.166del (p.Tyr56fs)	Likely pathogenic
3588655	NM_000685.5(AGTR1):c.337dup (p.Tyr113fs)	Likely pathogenic
3588656	NM_000685.5(AGTR1):c.340del (p.Ala114fs)	Likely pathogenic
50207	NM_000685.5(AGTR1):c.376C>T (p.Arg126Ter)	Likely pathogenic
814486	GRCh37/hg19 3q24-25.1(chr3:144053029-150272658)x1	Likely pathogenic

SpliceAI

798 predictions. Top by Δscore:

Variant	Effect	Δscore
3:148740984:CCCA:C	acceptor_loss	1.0000
3:148740985:CCA:C	acceptor_loss	1.0000
3:148740986:CA:C	acceptor_loss	1.0000
3:148740988:G:GT	acceptor_loss	1.0000
3:148740988:GGT:G	acceptor_gain	1.0000
3:148709244:G:GG	donor_gain	0.9900
3:148724681:GTCC:G	donor_gain	0.9900
3:148740987:A:AG	acceptor_gain	0.9900
3:148740988:G:GG	acceptor_gain	0.9900
3:148740988:GGTGT:G	acceptor_gain	0.9900
3:148698125:CGGG:C	donor_loss	0.9800
3:148698126:GGGT:G	donor_loss	0.9800
3:148698129:TGAG:T	donor_loss	0.9800
3:148709240:GACA:G	donor_gain	0.9800
3:148698124:GCGG:G	donor_gain	0.9700
3:148698126:GG:G	donor_gain	0.9700
3:148698127:GG:G	donor_gain	0.9700
3:148698130:G:GC	donor_loss	0.9700
3:148709396:G:T	donor_gain	0.9700
3:148731319:C:A	donor_gain	0.9700
3:148739856:AG:A	donor_gain	0.9700
3:148740022:G:T	donor_gain	0.9700
3:148698128:G:GG	donor_gain	0.9600
3:148698131:A:AC	donor_loss	0.9600
3:148698132:G:C	donor_loss	0.9600
3:148724685:G:GG	donor_gain	0.9600
3:148740978:A:AG	acceptor_gain	0.9600
3:148709396:G:GT	donor_gain	0.9500
3:148738860:GGCT:G	donor_gain	0.9500
3:148738861:GCTG:G	donor_gain	0.9500

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000007579 (3:148708365 C>A), RS1000031525 (3:148722290 A>G), RS1000167694 (3:148702682 G>A,T), RS1000222985 (3:148696146 G>A,T), RS1000376053 (3:148729237 G>C), RS1000426050 (3:148735011 C>G,T), RS1000541694 (3:148729502 G>T), RS1000624822 (3:148703030 G>T), RS1000677989 (3:148709358 A>G), RS1000731274 (3:148709624 T>A), RS1000765650 (3:148736635 GA>G,GAA), RS1000982836 (3:148730726 C>T), RS1000997254 (3:148729849 C>T), RS1001083675 (3:148724218 G>A), RS1001183821 (3:148708009 C>T)

Disease associations

OMIM: gene MIM:106165 | disease phenotypes: MIM:145500, MIM:267430, MIM:601331, MIM:613801, MIM:604290

GenCC curated gene-disease

Disease	Classification	Inheritance
renal tubular dysgenesis of genetic origin	Strong	Autosomal recessive
essential hypertension, genetic	No Known Disease Relationship	Unknown

Mondo (7): essential hypertension (MONDO:0001134), renal tubular dysgenesis (MONDO:0017609), essential hypertension, genetic (MONDO:0007781), renal tubular dysgenesis of genetic origin (MONDO:0009970), renal dysplasia, cystic, susceptibility to (MONDO:0011037), retinitis pigmentosa 40 (MONDO:0013429), aceruloplasminemia (MONDO:0011426)

Orphanet (5): Renal tubular dysgenesis (Orphanet:3033), Renal tubular dysgenesis of genetic origin (Orphanet:97369), Retinitis pigmentosa (Orphanet:791), Aceruloplasminemia (Orphanet:48818), NON RARE IN EUROPE: Essential hypertension (Orphanet:243761)

HPO phenotypes

15 total (15 of 15 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000079	Abnormality of the urinary system
HP:0000252	Microcephaly
HP:0001426	Non-Mendelian inheritance
HP:0001562	Oligohydramnios
HP:0002009	Potter facies
HP:0002089	Pulmonary hypoplasia
HP:0002093	Respiratory insufficiency
HP:0002615	Hypotension
HP:0004421	Elevated systolic blood pressure
HP:0004492	Widely patent fontanelles and sutures
HP:0004972	Elevated mean arterial pressure
HP:0005117	Elevated diastolic blood pressure
HP:0008660	Renotubular dysgenesis
HP:0100519	Anuria

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002831_6	Lead levels in blood	2.000000e-06
GCST003989_43	Chin dimples	4.000000e-09
GCST003996_20	Monobrow	2.000000e-09
GCST008114_14	Type 2 diabetes	8.000000e-07
GCST008362_211	Birth weight	2.000000e-13
GCST008839_425	Height	1.000000e-07

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007906	synophrys measurement
EFO:0004344	birth weight

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D000075222	Essential Hypertension	C14.907.489.165
C537755	Renal dysplasia diffuse cystic (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2094256 (PROTEIN FAMILY), CHEMBL227 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

88 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 554,388 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1513	IRBESARTAN	4	31,667
CHEMBL191	LOSARTAN	4	88,932
CHEMBL938	SARALASIN	4	7,408
CHEMBL995	LOSARTAN POTASSIUM	4	11,860
CHEMBL1014	CANDESARTAN CILEXETIL	4	11,194
CHEMBL1017	TELMISARTAN	4	27,457
CHEMBL104	CLOTRIMAZOLE	4	56,325
CHEMBL1064	SIMVASTATIN	4	123,163
CHEMBL1069	VALSARTAN	4	38,585
CHEMBL111	RIMONABANT	4	15,726
CHEMBL1112	ARIPIPRAZOLE	4	24,205
CHEMBL1171837	PONATINIB	4	8,955
CHEMBL1200585	OXYMETHOLONE	4	5,113
CHEMBL1200692	OLMESARTAN MEDOXOMIL	4	17,268
CHEMBL1200934	NORGESTIMATE	4	7,839
CHEMBL1201244	ROCURONIUM	4	2,682
CHEMBL1201303	PYRVINIUM	4	1,797
CHEMBL1201304	INDOCYANINE GREEN ACID FORM	4	7,044
CHEMBL1201346	BALSALAZIDE	4	8,319
CHEMBL121	ROSIGLITAZONE	4	58,849
CHEMBL1221	SULCONAZOLE	4
CHEMBL125	MILTEFOSINE	4
CHEMBL1295	BUTOCONAZOLE	4
CHEMBL1336	SORAFENIB	4
CHEMBL1401	NITAZOXANIDE	4
CHEMBL1423	PIMOZIDE	4
CHEMBL1480	FELODIPINE	4
CHEMBL1533	DESOGESTREL	4
CHEMBL1601669	ALFACALCIDOL	4
CHEMBL163	RITONAVIR	4

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

15 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs12721226	Efficacy	3	losartan
rs275651	Efficacy	3	perindopril	Coronary Artery Disease
rs5182	Toxicity	3	Ace Inhibitors;Plain	Hypertension
rs5182	Efficacy	3	perindopril	Coronary Artery Disease
rs5186	Efficacy,Toxicity	3	Ace Inhibitors;Plain	Coronary Artery Disease
rs5186	Metabolism/PK	3	atorvastatin
rs5186	Efficacy	3	irbesartan	Hypertension;Hypertrophy;Left Ventricular
rs5186	Efficacy	3	candesartan	Heart Failure
rs5186	Efficacy	3	captopril	Diabetes Mellitus;Type 2
rs5186	Efficacy	3	nitrendipine	Hypertension
rs5186	Efficacy	3	losartan
rs5186	Efficacy	3	angiotensin II
rs5186	Efficacy	3	perindopril	Hypertension
rs5186	Efficacy	3	losartan	Liver Cirrhosis
rs5186	Toxicity	3	Thiazides;plain

PharmGKB variants

5 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs5182	AGTR1	3	3.00	2	perindopril;Ace Inhibitors;Plain
rs5186	AGTR1	3	3.75	11	Ace Inhibitors;Plain;captopril;candesartan;atorvastatin;irbesartan;losartan;perindopril;nitrendipine;Thiazides
rs275651	AGTR1	3	5.50	1	perindopril
rs2640543	AGTR1		0.00	0
rs12721226	AGTR1	3	0.00	1	losartan

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Angiotensin receptors

Most potent curated ligand interactions (45 total), top 25:

Ligand	Action	Affinity	Parameter
[3H]candesartan	Antagonist	10.29	pKd
candesartan	Antagonist	9.72	pIC50
EXP3174	Antagonist	9.49	pIC50
[125I][Sar1]Ang-II	Full agonist	9.48	pKd
[Sar1,Ile8]Ang-II	Antagonist	9.43	pKd
[125I][Sar1,Ile8]Ang-II	Partial agonist	9.43	pKd
[Sar1,Cha8]Ang-II	Partial agonist	9.33	pKd
angiotensin II	Full agonist	9.3	pIC50
[3H]A81988	Antagonist	9.24	pKd
[3H]L158809	Antagonist	9.18	pKd
[3H]eprosartan	Antagonist	9.1	pKd
saprisartan	Antagonist	9.1	pKi
[Sar1,Ala8]Ang-II	Antagonist	9.05	pKd
[3H]valsartan	Antagonist	9.0	pIC50
tasosartan	Antagonist	8.92	pIC50
[125I]EXP985	Antagonist	8.83	pKd
eprosartan	Antagonist	8.8	pIC50
irbesartan	Antagonist	8.8	pIC50
5-oxo-1-2-4-oxadiazol biphenyl	Antagonist	8.8	pIC50
[3H]irbesartan	Antagonist	8.71	pKd
losartan	Antagonist	8.7	pIC50
valsartan	Antagonist	8.61	pIC50
forasartan	Antagonist	8.6	pIC50
angiotensin III	Full agonist	8.5	pIC50
sparsentan	Antagonist	8.44	pKi

Binding affinities (BindingDB)

283 measured of 402 human assays (418 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
US8501750, 56	IC50	0.34 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 83	IC50	0.77 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 60	IC50	1 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 76	IC50	1 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 105	IC50	1 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 63	IC50	1.1 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 107	IC50	1.1 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 59	IC50	1.2 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 99	IC50	1.2 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 131	IC50	1.2 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 181	IC50	1.2 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 186	IC50	1.2 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 153	IC50	1.3 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 215	IC50	1.3 nM	US-8501750: Heterocyclic compound and use thereof
3-[2-[4-[[6-ethyl-3-[2-(2-methoxyphenyl)-2-oxoethyl]-2,4-dioxothieno[2,3-d]pyrimidin-1-yl]methyl]phenyl]phenyl]-1,2,4-oxadiazol-5-olate	IC50	1.4 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 127	IC50	1.4 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 143	IC50	1.4 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 157	IC50	1.4 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 197	IC50	1.4 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 209	IC50	1.4 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 221	IC50	1.4 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 73	IC50	1.5 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 135	IC50	1.5 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 136	IC50	1.5 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 142	IC50	1.5 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 148	IC50	1.5 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 150	IC50	1.5 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 152	IC50	1.5 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 198	IC50	1.5 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 205	IC50	1.5 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 58	IC50	1.6 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 129	IC50	1.6 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 130	IC50	1.6 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 180	IC50	1.6 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 210	IC50	1.6 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 225	IC50	1.6 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 121	IC50	1.7 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 132	IC50	1.7 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 140	IC50	1.7 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 144	IC50	1.7 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 145	IC50	1.7 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 158	IC50	1.7 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 194	IC50	1.7 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 116	IC50	1.8 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 117	IC50	1.8 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 149	IC50	1.8 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 203	IC50	1.8 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 214	IC50	1.8 nM	US-8501750: Heterocyclic compound and use thereof
2-[4-[(6-ethyl-2,4-dioxothieno[2,3-d]pyrimidin-1-yl)methyl]-3-methoxyphenyl]benzonitrile	IC50	1.9 nM	US-8501750: Heterocyclic compound and use thereof
US8501750, 222	IC50	1.9 nM	US-8501750: Heterocyclic compound and use thereof

ChEMBL bioactivities

1724 potent at pChembl≥5 of 1954 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.90	Kd	0.01259	nM	CHEMBL47177
10.90	Kd	0.01259	nM	CL-329167
10.70	Kd	0.01995	nM	CHEMBL416477
10.33	Kd	0.04677	nM	CHEMBL125218
10.30	IC50	0.05	nM	CHEMBL346728
10.30	Kd	0.05012	nM	CHEMBL293511
10.30	Kd	0.05012	nM	CHEMBL418226
10.25	Kd	0.05623	nM	CHEMBL92542
10.18	IC50	0.066	nM	SARALASIN
10.10	Kd	0.07943	nM	CHEMBL416477
10.10	IC50	0.08	nM	CHEMBL295854
10.09	Kd	0.08128	nM	CARBOXYLIC ACID METABOLITE
10.04	Kd	0.0912	nM	PRATOSARTAN
10.01	Kd	0.09772	nM	PRATOSARTAN
10.00	IC50	0.1	nM	CHEMBL2435828
10.00	IC50	0.1	nM	CHEMBL24322
10.00	IC50	0.1	nM	CHEMBL307318
10.00	IC50	0.1	nM	CHEMBL70935
10.00	IC50	0.1	nM	CHEMBL305238
10.00	IC50	0.1	nM	CHEMBL305017
10.00	IC50	0.1	nM	CHEMBL70789
10.00	IC50	0.1	nM	CHEMBL70843
10.00	IC50	0.1	nM	CHEMBL69721
10.00	IC50	0.1	nM	CHEMBL70370
10.00	IC50	0.1	nM	CHEMBL70161
10.00	IC50	0.1	nM	L-158809
10.00	IC50	0.1	nM	CHEMBL42775
10.00	IC50	0.1	nM	CHEMBL298417
9.85	IC50	0.14	nM	CHEMBL435811
9.80	Kd	0.1585	nM	CHEMBL313371
9.80	Ki	0.16	nM	ANGIOTENSIN II
9.80	Kd	0.1585	nM	CHEMBL44295
9.80	Kd	0.1585	nM	CHEMBL289391
9.77	Ki	0.17	nM	SARALASIN
9.77	IC50	0.17	nM	ENOLTASOSARTAN
9.71	Kd	0.195	nM	CARBOXYLIC ACID METABOLITE
9.70	IC50	0.2	nM	CHEMBL338027
9.70	Kd	0.1995	nM	CHEMBL88411
9.70	IC50	0.2	nM	CHEMBL293511
9.70	Kd	0.1995	nM	CHEMBL387040
9.70	IC50	0.2	nM	CHEMBL2369937
9.70	IC50	0.2	nM	CHEMBL311625
9.70	IC50	0.2	nM	CHEMBL70868
9.70	IC50	0.2	nM	CHEMBL303427
9.70	IC50	0.2	nM	CHEMBL430792
9.70	IC50	0.2	nM	CHEMBL302964
9.70	IC50	0.2	nM	CHEMBL308323
9.70	IC50	0.2	nM	CHEMBL311253
9.70	IC50	0.2	nM	CHEMBL73283
9.70	IC50	0.2	nM	CHEMBL71639

PubChem BioAssay actives

922 with measured affinity, of 3197 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
6-[(2S,3aR)-2-methyl-3a,4,5,6-tetrahydro-3H-pyrrolo[1,2-b][1,2]oxazol-2-yl]-2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]quinazolin-4-one	167381: Inhibition of angiotensin II-induced contractions in rabbit aorta in vitro.	kd	<0.0001	uM
2-[propyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyridine-3-carboxylic acid	167381: Inhibition of angiotensin II-induced contractions in rabbit aorta in vitro.	kd	<0.0001	uM
2-[butyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyridine-3-carboxylic acid	37542: Potency to antagonize the ability of angiotensin II to contract rabbit aorta	kd	<0.0001	uM
2-butyl-6-(2-methoxypropan-2-yl)-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]quinazolin-4-one	568789: Antagonist activity at angiotensin AT1 receptor	kd	<0.0001	uM
N,N-dimethyl-2-[4-oxo-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-c]pyridin-5-yl]acetamide	39047: Inhibition of Angiotensin II induced contractions in rabbit aortic rings	ic50	0.0001	uM
N-tert-butyl-2-[2-butyl-4-oxo-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-c]pyridin-5-yl]acetamide	39047: Inhibition of Angiotensin II induced contractions in rabbit aortic rings	ic50	0.0001	uM
tert-butyl N-[2-[4-[[3-butyl-1-[2-chloro-5-(3-methoxypropanoylamino)phenyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-fluorophenyl]phenyl]sulfonylcarbamate	39659: In vitro inhibitory activity against angiotensin II receptor type 1, in human adrenal membrane preparations.	ic50	0.0001	uM
2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid	167381: Inhibition of angiotensin II-induced contractions in rabbit aorta in vitro.	kd	0.0001	uM
N-[2-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]phenyl]sulfonylbenzamide	167381: Inhibition of angiotensin II-induced contractions in rabbit aorta in vitro.	kd	0.0001	uM
3-[butyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyridazine-4-carboxylic acid	37542: Potency to antagonize the ability of angiotensin II to contract rabbit aorta	kd	0.0001	uM
2-ethyl-5,7-dimethyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine	39047: Inhibition of Angiotensin II induced contractions in rabbit aortic rings	ic50	0.0001	uM
2-[2-butyl-4-oxo-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-c]pyridin-5-yl]-N,N-diethylacetamide	39047: Inhibition of Angiotensin II induced contractions in rabbit aortic rings	ic50	0.0001	uM
(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid	31303: Inhibitory activity as antagonist of AII on guinea pig ileum	ic50	0.0001	uM
2-[4-[[4-methyl-6-(3-phenylpropanoylamino)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzoic acid	774875: Displacement of [125I]-Sar1Ile8-angiotensin 2 from angiotensin 2 AT1 receptor (unknown origin) after 180 mins by gamma counting analysis	ic50	0.0001	uM
2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6,7,8-tetrahydrocyclohepta[d]imidazol-4-one	167381: Inhibition of angiotensin II-induced contractions in rabbit aorta in vitro.	kd	0.0001	uM
3-[2-butyl-4-oxo-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]quinazolin-6-yl]-1-methyl-1-propan-2-ylurea	254757: Inhibitory concentration against angiotensin II receptor, type 1	ic50	0.0001	uM
2-ethyl-4-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methoxy]-5,6,7,8-tetrahydroquinoline	167381: Inhibition of angiotensin II-induced contractions in rabbit aorta in vitro.	kd	0.0001	uM
N-[2-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]phenyl]sulfonyl-2,2-diphenylacetamide	38124: Inhibition of Angiotensin II receptor, type 1	ic50	0.0001	uM
(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoic acid	31303: Inhibitory activity as antagonist of AII on guinea pig ileum	ic50	0.0002	uM
5-butyl-2-(2-phenylethyl)-4-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,2,4-triazol-3-one	166678: Antagonism of angiotensin-II mediated contraction of rabbit aortic rings expressed as pA2 (in vitro)	kd	0.0002	uM
methyl 2-[2-butyl-4-oxo-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-c]pyridin-5-yl]acetate	39047: Inhibition of Angiotensin II induced contractions in rabbit aortic rings	ic50	0.0002	uM
2-butyl-5-(2-oxo-2-pyrrolidin-1-ylethyl)-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-c]pyridin-4-one	39047: Inhibition of Angiotensin II induced contractions in rabbit aortic rings	ic50	0.0002	uM
4-[propyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyrimidine-5-carboxylic acid	37542: Potency to antagonize the ability of angiotensin II to contract rabbit aorta	kd	0.0002	uM
3-[propyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyridazine-4-carboxylic acid	37542: Potency to antagonize the ability of angiotensin II to contract rabbit aorta	kd	0.0002	uM
3-[butyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyrazine-2-carboxylic acid	37542: Potency to antagonize the ability of angiotensin II to contract rabbit aorta	kd	0.0002	uM
6-fluoro-2-[propyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyridine-3-carboxylic acid	37542: Potency to antagonize the ability of angiotensin II to contract rabbit aorta	kd	0.0002	uM
4-methyl-2-[propyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyridine-3-carboxylic acid	37542: Potency to antagonize the ability of angiotensin II to contract rabbit aorta	kd	0.0002	uM
Angiotensin Ii	1289936: Displacement of [3H]-Asp-{Nomega-[N-(4-propanoylaminobutyl)aminocarbonyl]}Arg-ValTyr-Ile-His-Pro-Phe-OH Tris(hydrotrifluoroacetate) from human AT1 receptor transfected in CHO cells co-expressing Galpha16-mtAEQ after 2 hrs by liquid scintillation counting	ki	0.0002	uM
2-ethyl-5-(2-oxo-2-piperidin-1-ylethyl)-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-c]pyridin-4-one	39047: Inhibition of Angiotensin II induced contractions in rabbit aortic rings	ic50	0.0002	uM
(2R)-2-[[(2R)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-2-methyl-3-phenylpropanoic acid	167386: pA2 value was determined in the range of competitive inhibition in the in vitro rabbit aorta strip assay.	kd	0.0002	uM
5-hydroxy-2,4-dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrido[2,3-d]pyrimidin-7-one	39655: Compound was tested for inhibition against Angiotensin II receptor, type 1	ic50	0.0002	uM
(3S)-4-[[(2S)-5-(diaminomethylideneamino)-1-[[(2S)-1-[[(2S)-3-(4-hydroxyphenyl)-1-[[(2S,3S)-1-[[(2S)-3-(1H-imidazol-5-yl)-1-[[(2S)-3-(1H-imidazol-5-yl)-1-[[(2S,3S)-3-methyl-1-oxo-1-[[(2S)-3-oxo-1-phenylbutan-2-yl]amino]pentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-(methylamino)-4-oxobutanoic acid	39195: Binding affinity towards Angiotensin receptor from rabbit aorta	ic50	0.0002	uM
tert-butyl N-[2-[4-[[1-[2-bromo-5-(pentanoylamino)phenyl]-3-ethyl-5-oxo-1,2,4-triazol-4-yl]methyl]-3-fluorophenyl]phenyl]sulfonylcarbamate	38124: Inhibition of Angiotensin II receptor, type 1	ic50	0.0002	uM
2-[2-butyl-4-oxo-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-c]pyridin-5-yl]-N,N-dimethylacetamide	39047: Inhibition of Angiotensin II induced contractions in rabbit aortic rings	ic50	0.0002	uM
N-[2-[4-[[3-butyl-1-[2-chloro-5-(propanoylamino)phenyl]-5-oxo-1,2,4-triazol-4-yl]methyl]-3-fluorophenyl]phenyl]sulfonyl-2-chlorobenzamide	39659: In vitro inhibitory activity against angiotensin II receptor type 1, in human adrenal membrane preparations.	ic50	0.0003	uM
2-[2-ethyl-4-oxo-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-c]pyridin-5-yl]-N,N-dimethylacetamide	39047: Inhibition of Angiotensin II induced contractions in rabbit aortic rings	ic50	0.0003	uM
tert-butyl N-[2-[4-[[3-butyl-1-[2-chloro-5-(propanoylamino)phenyl]-5-oxo-1,2,4-triazol-4-yl]methyl]phenyl]phenyl]sulfonylcarbamate	39659: In vitro inhibitory activity against angiotensin II receptor type 1, in human adrenal membrane preparations.	ic50	0.0003	uM
tert-butyl N-[2-[4-[[1-[2-bromo-5-(propanoylamino)phenyl]-5-oxo-3-propyl-1,2,4-triazol-4-yl]methyl]-3-fluorophenyl]phenyl]sulfonylcarbamate	39659: In vitro inhibitory activity against angiotensin II receptor type 1, in human adrenal membrane preparations.	ic50	0.0003	uM
ethyl N-[2-[4-[[3-butyl-5-oxo-1-[5-(propanoylamino)-2-(trifluoromethyl)phenyl]-1,2,4-triazol-4-yl]methyl]-3-fluorophenyl]phenyl]sulfonylcarbamate	39659: In vitro inhibitory activity against angiotensin II receptor type 1, in human adrenal membrane preparations.	ic50	0.0003	uM
5-[(5,7-dimethyl-2-propylimidazo[4,5-b]pyridin-3-yl)methyl]-9-(2H-tetrazol-5-yl)tricyclo[9.4.0.03,8]pentadeca-1(15),3(8),4,6,9,11,13-heptaen-2-one	39665: Ability to displace [125I]AII binding to COS cells transfected with a cDNA encoding human Angiotensin II receptor, type 1	ki	0.0003	uM
N-[2-[4-[[3-butyl-5-oxo-1-[5-(propanoylamino)-2-(trifluoromethyl)phenyl]-1,2,4-triazol-4-yl]methyl]-3-fluorophenyl]phenyl]sulfonyl-2-chlorobenzamide	39660: In vitro inhibitory activity against Angiotensin II receptor, type 1 in human adrenal membrane preparations. For this assay, only 0.02%BSA was present in the assay mixture.	ic50	0.0003	uM
2-methyl-4-[propyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyrimidine-5-carboxylic acid	37542: Potency to antagonize the ability of angiotensin II to contract rabbit aorta	kd	0.0003	uM
N,N-diethyl-2-[2-ethyl-4-oxo-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-c]pyridin-5-yl]acetamide	39047: Inhibition of Angiotensin II induced contractions in rabbit aortic rings	ic50	0.0003	uM
2-[2-butyl-4-oxo-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-c]pyridin-5-yl]-N-methyl-N-phenylacetamide	39047: Inhibition of Angiotensin II induced contractions in rabbit aortic rings	ic50	0.0003	uM
N-[2-[4-[[3-butyl-5-oxo-1-[5-(propanoylamino)-2-(trifluoromethyl)phenyl]-1,2,4-triazol-4-yl]methyl]-3-fluorophenyl]phenyl]sulfonylbenzamide	39659: In vitro inhibitory activity against angiotensin II receptor type 1, in human adrenal membrane preparations.	ic50	0.0003	uM
5,7-dimethyl-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine	39195: Binding affinity towards Angiotensin receptor from rabbit aorta	ic50	0.0003	uM
Losartan	673042: Inhibition of angiotensin AT1 receptor	ic50	0.0003	uM
(2S)-2-[[(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-[4-[3-(trifluoromethyl)diazirin-3-yl]phenyl]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid	466198: Displacement of [125I][Sar1,Ile8]Ang2 from human AT1 receptor N111G constitutively active mutant expressed in CHO cells by gamma counting	ki	0.0003	uM
4-[butyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]pyrimidine-5-carboxylic acid;hydrochloride	37542: Potency to antagonize the ability of angiotensin II to contract rabbit aorta	kd	0.0003	uM
5-[2-[4-[[4-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-1-ium-1-yl]methyl]phenyl]phenyl]-2H-tetrazole bromide	736072: Displacement of [125I-Sar1-Ile8]-ANG2 from human Angiotensin 2 type-1 receptor expressed in HEK293 cells after 1 hr by gamma counting analysis	ic50	0.0003	uM

CTD chemical–gene interactions

76 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	decreases reaction, increases expression, decreases expression	4
Cyclosporine	affects cotreatment, affects expression, decreases expression, decreases methylation	4
bisphenol A	decreases methylation, increases expression, affects cotreatment, increases methylation	3
Glucose	decreases reaction, increases expression	3
Tetrachlorodibenzodioxin	affects expression, decreases expression	3
Valproic Acid	affects expression, increases expression	3
Aflatoxin B1	decreases methylation, affects expression, decreases expression	3
Losartan	affects binding, decreases activity, decreases abundance, increases expression	3
sodium arsenite	affects reaction, increases expression, affects binding, increases reaction	2
potassium chromate(VI)	affects cotreatment, decreases expression, increases expression	2
epigallocatechin gallate	decreases reaction, increases expression, increases reaction, affects cotreatment, decreases expression	2
Irbesartan	affects response to substance, affects binding, decreases activity	2
Acetaminophen	decreases expression	2
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	2
Tretinoin	decreases expression, increases expression	2
Simvastatin	decreases expression	2
diminazene aceturate	affects reaction, decreases reaction, increases expression	1
propionaldehyde	decreases expression	1
steviol	increases expression	1
stevioside	increases expression	1
arsenite	increases methylation	1
butyraldehyde	decreases expression	1
3,4,5,3’,4’-pentachlorobiphenyl	increases expression	1
rebaudioside A	increases expression	1
mercuric bromide	increases expression	1
benazepril	affects cotreatment, affects response to substance	1
pentanal	decreases expression	1
chromium hexavalent ion	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
candesartan	affects binding, decreases activity	1

ChEMBL screening assays

421 unique, capped per target: 315 binding, 105 functional, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4327279	Binding	Antagonist activity at angiotensin-2 receptor (unknown origin)	Naphthalene, a versatile platform in medicinal chemistry: Sky-high perspective. — Eur J Med Chem
CHEMBL642870	Functional	The compound was tested for its inhibitory activity as antagonist of AII on guinea pig ileum	Synthesis and biological activity of angiotensin II analogues containing a Val-His replacement, Val psi[CH(CONH2)NH]His. — J Med Chem
CHEMBL4810226	ADMET	Inhibition of human angiotensin 2, AT1 at 0.1 to 1 uM	Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor. — J Med Chem

Cellosaurus cell lines

9 cell lines: 5 cancer cell line, 3 transformed cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B7VU	Abcam Raji AGTR1 KO	Cancer cell line	Male
CVCL_B9WC	Abcam THP-1 AGTR1 KO	Cancer cell line	Male
CVCL_C6YD	Abcam PC-3 AGTR1 KO	Cancer cell line	Male
CVCL_D7JU	Ubigene A-549 AGTR1 KO	Cancer cell line	Male
CVCL_E7HM	LhAT1-D6	Transformed cell line	Male
CVCL_H376	293T/AT1	Transformed cell line	Female
CVCL_H514	HEK293/AT1	Transformed cell line	Female
CVCL_KW31	PathHunter CHO-K1 AGTR1 beta-arrestin	Spontaneously immortalized cell line	Female
CVCL_ZJ96	Tango AGTR1-bla U2OS	Cancer cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00157963	PHASE4	COMPLETED	Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)
NCT00295555	PHASE4	COMPLETED	Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy
NCT00311155	PHASE4	COMPLETED	Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension
NCT00328965	PHASE4	COMPLETED	Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea
NCT00366119	PHASE4	UNKNOWN	Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension
NCT00408512	PHASE4	COMPLETED	Pharmacosurveillance and Pharmacogenetics of First-line Diuretics in Hypertension: The StayOnDiur Study
NCT00438945	PHASE4	COMPLETED	The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension
NCT00457483	PHASE4	COMPLETED	Nijmegen Antihypertensive Management Improvement Study
NCT00509470	PHASE4	COMPLETED	Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine
NCT00654875	PHASE4	COMPLETED	Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
NCT00716950	PHASE4	UNKNOWN	Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients
NCT00741585	PHASE4	COMPLETED	Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
NCT00765947	PHASE4	COMPLETED	Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
NCT00794885	PHASE4	COMPLETED	China Stroke Primary Prevention Trial
NCT00819104	PHASE4	COMPLETED	A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components
NCT00841308	PHASE4	UNKNOWN	Home Blood Pressure in Hypertension Management
NCT00890591	PHASE4	COMPLETED	Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
NCT00994617	PHASE4	UNKNOWN	Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension
NCT01011660	PHASE4	UNKNOWN	Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients
NCT01042392	PHASE4	COMPLETED	Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients
NCT01120990	PHASE4	COMPLETED	Hybrid Blood Pressure Monitor Validation
NCT01131546	PHASE4	COMPLETED	Efficacy and Safety of Levamlodipine Besylate Compared to Amlodipine Maleate in Patients With Essential Hypertension
NCT01132768	PHASE4	TERMINATED	The Confirmatory Olmesartan Plaque Regression Study
NCT01180413	PHASE4	COMPLETED	Intensive Vasodilator Therapy in Patients With Essential Hypertension
NCT01241487	PHASE4	COMPLETED	A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy
NCT01629225	PHASE4	UNKNOWN	GRK4 Polymorphisms Blood Pressure Response to Candesartan
NCT01825759	PHASE4	UNKNOWN	Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function
NCT02031861	PHASE4	COMPLETED	Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension
NCT02058446	PHASE4	COMPLETED	PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension
NCT02062645	PHASE4	COMPLETED	Study of Efficacy and Safety of CVAA489 in Hypertensive Patients
NCT02184858	PHASE4	COMPLETED	Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension
NCT02214498	PHASE4	UNKNOWN	Treatment of HYpertension: Morning Versus Evening
NCT02357615	PHASE4	UNKNOWN	Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure
NCT02517866	PHASE4	COMPLETED	Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
NCT02612298	PHASE4	COMPLETED	Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate
NCT02687178	PHASE4	COMPLETED	Canrenone as Add-on in Patients With Essential Hypertension
NCT03226340	PHASE4	UNKNOWN	S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension
NCT04306627	PHASE4	UNKNOWN	Effect of Atorvastatin on Carotid Intima Media Thickness
NCT05683301	PHASE4	COMPLETED	Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India
NCT05843162	PHASE4	UNKNOWN	A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome